Pharmaceutical Technology

NOVEMBER 21, 2022

Imago BioSciences founder and CEO Dr Hugh Rienhoff said: “This agreement leverages Merck’s industry-leading clinical development expertise to maximise the therapeutic potential of bomedemstat while providing important value for shareholders.”.

Clinical Trials 246

Clinical Trials Clinical Trials Sales Clinical Development 246

Pharmaceutical Technology

JANUARY 16, 2023

Monash University will also receive milestone payments on clinical development and sales progress, along with royalties based on net sales of the products in the future, if the option is exercised by Ono Pharmaceutical under the deal.

Research 130

Research Antibody Sales Development 130

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. source Link.

Clinical Development 52

Clinical Development Medicine Development Containment 52

Pharmaceutical Technology

JUNE 15, 2023

The deal gives Astellas the option to exclusively license its rights for clinical development and commercialisation for any protein degrader compounds developed within the lead programme. Astellas may also give Cullgen royalty payments based on potential sales.

Protein 130

Protein Development Licensing Licensing 130

Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development 130

Development Drugs Bioavailability Production 130

Pharmaceutical Technology

JUNE 2, 2023

Furthermore, Amarin will receive tiered double-digit percentage royalties on the net sales of Vascepa in the territory. As a result of obtaining the NMPA approval, EDDING has to pay $5m as a regulatory milestone payment to Amarin.

Clinical Trials 130

Clinical Trials Clinical Trials Sales Clinical Development 130

BioTech 365

SEPTEMBER 22, 2020

TPG Capital establishes new entity to continue the development of select clinical assets spun-out of Adare Pharmaceuticals Announcement follows TPG Capital’s sale of Adare Pharmaceuticals’ specialty CDMO pharmaceutical technology and microbiome businesses SAN FRANCISCO & FORT WORTH, Texas–(BUSINESS WIRE)–TPG Capital, … (..)

Clinical Development 40

Clinical Development Development Sales 40

BioPharma Reporter

APRIL 25, 2024

A recent Deloitte report revealed that 36% of healthcare product launches fell short of achieving 80% of their sales targets within the first two years.

Production 59

Production Sales Clinical Development Development 59

Pharmaceutical Technology

FEBRUARY 17, 2023

Capricor will handle the clinical development of CAP-1002 and sell commercial products to Nippon Shinyaku. Additionally, Capricor will receive up to $89m in further development and sales-based milestones, along with a double-digit share of revenue based on product sales.

Gene Therapy 130

Gene Therapy Sales Clinical Development Gene 130

Pharmaceutical Technology

APRIL 25, 2023

Spectrum is a commercial-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel and targeted oncology treatments. The company has its own clinical development organisation equipped with regulatory and data management competencies.

Sales 130

Sales Clinical Development Development Production 130

The Pharma Data

SEPTEMBER 29, 2021

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 The Bayer brand stands for trust, reliability and quality throughout the world.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

The Pharma Data

MAY 2, 2021

Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1.

Clinical Development 40

Clinical Development Medicine Development Production 40

Pharmaceutical Technology

DECEMBER 7, 2022

HotSpot is also entitled to get option fees and research and development milestone payments totalling up to $295m. Additionally, AbbVie could make commercial milestone and tiered royalty payments on global net sales in the future to HotSpot.

Sales 147

Sales Development Clinical Development Antibody 147

Pharmaceutical Technology

JUNE 28, 2022

Astellas and Sutro will expedite the development of iADCs for three different biological targets. Sutro will oversee the research and preclinical research to detect candidate compounds and subsequently Astellas will carry out the clinical development. Furthermore, the company is entitled to get up to $422.5m

Development 264

Development Antibody Immune Response Production 264

Pharmaceutical Technology

AUGUST 4, 2022

The company could also receive a total of up to $6bn in research, development, launch and net sales milestones and other payments, in addition to tiered royalty payments on net product sales, across various programmes.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

pharmaphorum

JANUARY 5, 2022

GlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. There’s also regulatory annd sales milestones totaling up to $200 million at the back end of the deal, and BioNTech will also get a share of gross profits from any future sales.

Vaccination 102

Vaccination Vaccine Sales Clinical Development 102

Pharmaceutical Technology

JANUARY 4, 2023

Under the deal terms, the two companies will work together to advance the preclinical development of RA and lupus immunotherapies. Gilead will be responsible for the clinical development and commercialisation and holds the rights to exclusively license the NanoDisc technology of EVOQ for the product candidates.

Licensing 130

Licensing Licensing Sales Clinical Development 130

Pharmaceutical Technology

DECEMBER 7, 2022

Clear Creek Bio is also entitled to receive further potential milestone payments as well as royalties on sales of products in the future. Under the agreement, Pfizer will make an undisclosed upfront payment to Clear Creek Bio.

Development 130

Development Clinical Trials Clinical Trials Sales 130

Outsourcing Pharma

OCTOBER 20, 2023

Dave Hine is the senior director of sales and engineering at Greenphire. He has been reflecting on his time at DPharm and the collaborative approach to life sciences.

Life Science 77

Life Science Engineer Sales Clinical Development 77

Pharmaceutical Technology

MARCH 23, 2023

The company also has several promising agents in early clinical development. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements. Seagen generated almost $2 billion in revenue in 2022, an increase approaching 25% from 2021.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

DECEMBER 14, 2022

Additionally, for WVE-006, GSK will make development and launch milestone payments of up to $225m to Wave, which is also eligible to get up to $300m in milestone payments based on sales. On completion of the first-in-patient clinical trial by Wave, GSK will be in charge of the development and marketing works.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia.

Medicine 100

Medicine Hormones Production Clinical Trials 100

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Looking at the targets, the majority of drugs in clinical development focus on CD19, said Chalk, noting that these are agents for blood malignancies. This high compound annual growth rate of 23.6%

Marketing 264

Marketing Vaccination Vaccine Development 264

The Pharma Data

FEBRUARY 24, 2022

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 The Bayer brand stands for trust, reliability and quality throughout the world.

Clinical Development 52

Clinical Development Development Cardiology Life Science 52

Drug Discovery World

APRIL 17, 2024

The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 programme, a splice variant of the AR. Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR.

Protein 52

Protein Licensing Licensing Sales 52

Pharmaceutical Technology

NOVEMBER 18, 2022

According to the agreement, CytomX will receive a $30m upfront payment and is eligible to receive up to $2bn in preclinical, clinical, and commercial milestones. The company will also receive tiered global net sales royalties.

Development 130

Development Antibody Licensing Licensing 130

Pharmaceutical Technology

FEBRUARY 24, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Sales 113

Sales Production Clinical Trials Clinical Trials 113

Pharmaceutical Technology

FEBRUARY 20, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Sales 100

Sales Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

AUGUST 17, 2022

Preclinical data showed the potential of oRNA expression and delivery as a method for advanced development in various areas, including vaccines and oncology treatments. Merck will also make royalty payments on any approved products developed out of the partnership.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

MAY 31, 2023

Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). The company’s pipeline products include Busulipo which is under Phase II clinical trials and Nefecon for IgA Nephritis which is under Phase II clinical trials.

Clinical Trials 100

Clinical Trials Clinical Trials Production Licensing 100

Pharmaceutical Technology

AUGUST 24, 2022

Prevail will also handle the complete production, clinical development and marketing activities. Lacerta is entitled to receive an upfront payment as well as development and commercial milestone payments from Prevail.

Development 130

Development Gene Therapy Genetics Gene 130

Pharmaceutical Technology

MARCH 1, 2023

Orvacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Pharmacy 100

Pharmacy Production Clinical Trials Clinical Trials 100

pharmaphorum

NOVEMBER 18, 2022

Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will receive $30 million in an upfront payment , with the potential for up to $2 billion in research, development, regulatory, and sales-based milestones, also.

Antibody 101

Antibody Sales Development Licensing 101

Pharmaceutical Technology

JUNE 6, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RNA 100

RNA Protein Antibody Vaccination 100

Pharmaceutical Technology

JANUARY 2, 2023

Danicamtiv is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Drugs 100

Drugs Pharmacy Production Development 100

pharmaphorum

MARCH 15, 2022

In return, it will get a royalty on sales if the new version gets approved. It’s an example of a fairly uncommon risk-sharing model, in which an investment group funds a clinical development programme in the hope of a bigger payoff down the line, with rights to the drug staying with the pharma partner.

Trials 93

Trials Sales Drug Delivery Antibody 93